CRP and rheumatoid arthritis: Lee YH et al. [85] conducted a network meta-analysis and included information from RTC that examined remission DAS28-CRP by tofacitinib, baricitinib, upadacitinib, filgotinib monotherapy, and MTX in DMARDs-naive RA patients.